PETER G. TRABER, M.D.

Corporate Board Profile

Tech Score: 20/100

← Back to All Directors

Software Technology Evidence

2 mention(s) identify PETER G. TRABER, M.D. as having software/technology expertise.

Company Filing Date Evidence Reason
GALECTIN THERAPEUTICS INC 2012-04-20 Dr. Traber received his M.D. from Wayne State School of Medicine and a B.S. in chemical engineering from the University of Michigan. He was Chairman and CEO of TerraSep, LLC, a biotechnology company. Dr. Traber holds a B.S. in chemical engineering and has served as Chief Medical Officer and CEO, with experience in biotechnology and medical technology companies, indicating technical expertise that may include programming.
GALECTIN THERAPEUTICS INC 2016-11-10 Dr. Traber received his M.D. from Wayne State School of Medicine and a B.S. in chemical engineering from the University of Michigan. Dr. Traber was the Chairman of the Board and Chief Executive Officer of TerraSep, LLC, a Mountain View, CA biotechnology company. Dr. Traber has a B.S. in chemical engineering and has served as CEO of a biotechnology company with a technology focus, indicating technical expertise that may include programming.

GALECTIN THERAPEUTICS INC

Filing Date Source Excerpt
2011-04-12 Dr. Traber received his M.D. from Wayne State School of Medicine and a B.S. in chemical engineering from the University of Michigan. We believe Dr. Traber’s qualifications to sit on our Board of Directors include his years of medical experience in the pharmaceutical and healthcare industries, as well as the deep understanding of our patients and our products.
2012-04-20 Dr. Traber received his M.D. from Wayne State School of Medicine and a B.S. in chemical engineering from the University of Michigan. He was Chairman and CEO of TerraSep, LLC, a biotechnology company.
2013-04-12 Dr. Traber received his M.D. and a B.S. in chemical engineering. He has served as CEO, President, and Chief Medical Officer, with extensive industry and company-specific experience.
2014-03-21 Dr. Traber received his M.D. and a B.S. in chemical engineering, and has served as CEO and Chief Medical Officer, with no mention of programming or software engineering experience.
2015-04-08 Dr. Traber received his M.D. from Wayne State School of Medicine and a B.S. in chemical engineering from the University of Michigan. He has served as CEO and Chief Medical Officer of the company.
2016-11-10 Dr. Traber received his M.D. from Wayne State School of Medicine and a B.S. in chemical engineering from the University of Michigan. Dr. Traber was the Chairman of the Board and Chief Executive Officer of TerraSep, LLC, a Mountain View, CA biotechnology company.

LISATA THERAPEUTICS, INC.

Filing Date Source Excerpt
2018-04-24 Peter G. Traber, M.D. joined the Caladrius Board in January 2015. ... Our Compensation Committee consists of four directors: Mr. Klosk (Chairman), Dr. Brown, Mr. Myers and Dr. Traber. ... Our Nominating and Governance Committee consists of three directors: Mr. Myers (Chairman), Dr. Brown and Dr. Traber. ... Science and Technology Committee: The Science and Technology Committee consists of Drs. Traber (Chairman), Brown, Mazzo and Mr. Klosk. ... The following table sets forth information on all compensation to Caladrius' directors (other than as reflected in the Summary Compensation Table) for the year ended December 31, 2017. ... Peter G. Traber, M.D. $58,000 cash fees, $19,615 stock awards, $6,380 option awards, total $83,995.
2019-04-30 Dr. Traber joined the Caladrius Board in January 2015. The Compensation Committee consists of four directors: Mr. Klosk (Chairman), Dr. Brown, Mr. Myers and Dr. Traber. Our Nominating and Governance Committee consists of three directors: Mr. Myers (Chairman), Dr. Brown and Dr. Traber. The Science and Technology Committee consists of Drs. Traber (Chairman), Brown, Mazzo and Mr. Klosk and Ms. Schwalm. The following table sets forth information on all compensation to Caladrius' directors for the year ended December 31, 2018. Peter G. Traber, M.D.: Fees Earned in Cash $59,500, Stock Awards $33,151, Total Compensation $101,402.
2020-04-29 Dr. Traber joined the Caladrius Board in January 2015. He has extensive experience in medicine, science and the pharmaceutical industry. The Caladrius Board has concluded that Dr. Traber should continue serving as a director based on his diverse experience in healthcare, including his expertise in clinical trial design and product development, and his management experience. The Compensation Committee consists of four directors: Mr. Klosk (Chairman), Dr. Brown, Mr. Myers and Dr. Traber. The Nominating and Governance Committee consists of three directors: Mr. Myers (Chairman), Dr. Brown and Dr. Traber. The Science and Technology Committee consists of Drs. Traber (Chairman), Brown, Mazzo, Mr. Klosk and Ms. Schwalm. The following table sets forth information on all compensation to Caladrius' directors (other than as reflected in the Summary Compensation Table) for the year ended December 31, 2019. Peter G. Traber, M.D.: Fees Earned or Paid in Cash $59,500; Stock Awards $59,999; Total Compensation $119,499.
2021-04-28 Peter G. Traber, M.D. joined the Caladrius Board in January 2015. ... Our Nominating and Governance Committee consists of three directors: Mr. Myers (Chairman), Dr. Davidson and Dr. Traber. ... The Science and Technology Committee consists of Drs. Davidson (Chairman), Brown, Traber, Mazzo, Mr. Klosk, Ms. Schwalm and Ms. Whitaker. ... The following table sets forth information on all compensation to Caladrius' directors (other than as reflected in the Summary Compensation Table) for the year ended December 31, 2020. ... Peter G. Traber, M.D. $58,375 Fees Earned in Cash, $59,998 Stock Awards, $0 Option Awards, $118,373 Total Compensation.

Data sourced from SEC filings. Last updated: 2026-02-03